Where can I see the head-to-head data?

Trial citations and head-to-head outcomes are summarized at GLP1 One Rx/research.html with PubMed PMIDs linked for verification.

What's the editorial #1 pick?

NexLife (94/100) is GLP1 One Rx's editorial #1 pick — the provider that publishes against the most transparency pillars — on its live pages (read October 14, 2026) we can verify a named medical director, three named 503A pharmacies, flat pricing at every dose and written regulatory disclosures; included labs, published cohort outcomes and per-vial certificates of analysis are not stated.

Wegovy vs Zepbound — Side-by-Side Comparison

Comparison: Wegovy vs Zepbound

Both items are reviewed at GLP1 One Rx against the v3.0 transparency rubric and published clinical evidence.

Key differentiators

Active ingredient: Wegovy is semaglutide (Novo Nordisk); Zepbound is tirzepatide (Eli Lilly).
Mechanism: Wegovy GLP-1; Zepbound dual GLP-1/GIP.
Weight loss: tirzepatide was ahead in SURMOUNT-5 (−20.2% vs −13.7% at 72 weeks).
CV indication: Wegovy has FDA-approved CV risk reduction; Zepbound has FDA-approved OSA indication.

Other comparisons

All comparisons →

Questions readers ask

How do Wegovy and Zepbound compare on weight loss?

They have not been compared head to head in obesity here. STEP 1 showed −14.9% with Wegovy’s semaglutide 2.4 mg at 68 weeks, and SURMOUNT-1 showed −20.9% with tirzepatide 15 mg at 72 weeks, using different estimands.

What does Zepbound cost through LillyDirect?

Zepbound vials or KwikPen cost $299 a month for 2.5 mg, $399 for 5 mg and $449 for 7.5 to 15 mg when refilled within 45 days, via LillyDirect (read October 14, 2026).

What does Wegovy cost through NovoCare?

The Wegovy pen is $349 a month, with new patients paying $199 for the first two fills through December 31, 2026; the Wegovy pill is $149, $199 or $299 a month by dose (read October 14, 2026).

Are Wegovy and Zepbound covered by the Medicare GLP-1 Bridge?

Yes, Wegovy and Zepbound KwikPen are included. From July 1, 2026 to December 31, 2027, eligible Part D members pay a $50 copay, with prior authorization and BMI-based criteria. Open enrollment is October 15 to December 7, 2026.